6533b85bfe1ef96bd12ba871
RESEARCH PRODUCT
Novel therapeutic options and drug targets in MS
Axel MethnerFrauke Zippsubject
DrugPhase iii trialsbusiness.industryMultiple sclerosismedia_common.quotation_subjectPharmacologymedicine.diseaseBioinformaticsCellular and Molecular NeurosciencemedicineNeurology (clinical)businessTumor necrosis factor receptormedia_commondescription
2012 witnessed important developments for multiple sclerosis, including successful phase III trials of novel oral therapeutics and identification of the potassium channel KIR4.1 as an autoimmune target. Additionally, the lung was highlighted as an important site for immune-cell programming, and the relevance of a TNF receptor variant was clarified.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2013-01-22 | Nature Reviews Neurology |